Tspyl5 Protein Can Help Better Identify Prostate Cancer Progression

Early detection is critical for success in the treatment of prostate cancer. Hence, reliable markers for the malignancy play a vital role in reducing the mortality rate among patients.

Prostate Cancer

Prostate cancer is the most common malignancy reported in adult men. Most patients who develop prostate cancer show no symptoms initially. It is only when the prostate is large enough to affect the urinary system that the malignancy is finally diagnosed. This poses a major challenge in reducing the mortality and morbidity of cancer and hence, finding reliable biomarkers is important in the fight against prostate cancer.

Also read: Prostate Cancer 2

PSA Test

At present, Prostate-specific antigen (PSA), a substance produced by the prostate gland, is used as a marker for prostate cancer. Elevated levels of PSA are used to detect the presence of the malignant cells. However, a high level of PSA does not necessarily indicate the presence of prostate cancer. It could merely be the result of an inflamed or enlarged prostate, both of which are a natural part of the aging process. More reliable tests are needed to help the medical community detect and treat the disease in the increasingly aging population in developed countries.

New Biomarker

In this context, a recent study by researchers holds special significance. Preliminary studies have identified a specific protein (TSPYL5), which may allow for better identification of prostate cancer progression, and allow for more effective treatment. In addition, the presence of TSPYL5 also seemed to increase the sensitivity of cancer cells to chemotherapy drugs. So measuring the levels of TSPYL5 might be a way to diagnose the patients who have a more aggressive form of the disease.

To quote researcher Senthil Kumar, “TSPYL5 testing could become one of the tools in our fight against prostate cancer. The anticipation is that we can use this biomarker for patients before they undergo any unnecessary and invasive surgeries or drug therapy plans.” Further studies are underway to confirm the validity of these findings

To know more: Testis Specific Y-like 5: Gene Expression, Methylation And Implications For Drug Sensitivity In Prostate Carcinoma

Leave a reply